CUPR (Cuprina Holdings Ltd) Short-Term Debt to Capital

The efficiency of Cuprina Holdings (Cayman) Ltd (CUPR) relies on the implementation of innovative larval therapy for healing skin damage, where success depends on sterility and medical approval. The Singaporean project is developing a network of Asian hospitals and distributors, and the asset's market valuation dynamics on GURU.Markets stand at 0.03. However, the business faces pressure from biogel developers and the risk of acquisition by corporate behemoths.

Fundamental asset selection requires a rigorous analysis of the liability structure to assess business resilience to credit risks. This indicator measures the proportion of obligations maturing within one year relative to equity, which is critical for Cuprina Holdings (CUPR) during prolonged waits for regulatory approvals of new treatments, reflecting current liquidity and the level of financial pressure via the short-term leverage ratio.